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Abstract
Objective:  To  review  the  mechanisms  of  action  of  macrolides  in  pediatric  respiratory  diseases
and their  clinical  indications.
Sources:  Review  in  the  PubMed  database,  comprising  the  following  terms  in  English:  ‘‘macrolide
and asthma’’;  ‘‘macrolide  and  cystic  ﬁbrosis’’;  ‘‘macrolide  bronchiolitis  and  viral  acute’’;
‘‘macrolide  and  bronchiolitis  obliterans’’  and  ‘‘macrolide  and  non-CF  bronchiectasis’’.
Summary  of  the  ﬁndings:  The  spectrum  of  action  of  macrolides  includes  production  of
inﬂammatory  mediators,  control  of  mucus  hypersecretion,  and  modulation  of  host-defense
mechanisms.  The  potential  beneﬁt  of  macrolide  antibiotics  has  been  studied  in  a  variety  of  lung
diseases, such  as  cystic  ﬁbrosis  (CF),  bronchiectasis,  asthma,  acute  bronchiolitis,  and  non-CF
bronchiectasis.  Several  studies  have  evaluated  the  beneﬁts  of  macrolides  in  asthma  refrac-
tory to  therapy,  but  the  results  are  controversial  and  indications  should  be  limited  to  speciﬁc
phenotypes. Please cite this article as: da Silva Filho LV, Pinto LA, Stein RT. Use of macrolides in lung diseases: recent literature controversies. J
ediatr (Rio J). 2015;91:S52--60.
∗ Corresponding author.
E-mail: rstein@pucrs.br (R.T. Stein).
ttp://dx.doi.org/10.1016/j.jped.2015.08.002
021-7557/© 2015 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.
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In  viral  bronchiolitis,  there  is  no  consistent  beneﬁt  in  acute  conditions,  although  recent  data
have shown  an  effect  in  recurrent  wheezing  prevention.  In  patients  with  CF  results  are  also
contradictory,  but  the  consensus  states  there  is  a  small  clinical  beneﬁt,  especially  for  patients
infected with  P.  aeruginosa.  There  was  also  no  positive  action  of  macrolides  in  patients  with
post-infectious  bronchiolitis  obliterans.  Children  with  non-CF  bronchiectasis  seem  to  have  clear
beneﬁts regarding  the  use  of  macrolides,  which  showed  clinical  advantages  in  parenchyma
protection  and  lung  function.
Conclusions:  The  long-term  use  of  macrolides  should  be  limited  to  highly  selected  situations,
especially  in  patients  with  bronchiectasis.  Careful  evaluation  of  the  beneﬁts  and  potential
damage are  tools  for  their  indication  in  speciﬁc  groups.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Uso  de  macrolídeos  em  doenc¸as pulmonares:  controvérsias  da  literatura  recente
Resumo
Objetivo:  revisar  os  mecanismos  de  ac¸ão  de  macrolídeos  em  doenc¸as  respiratórias  pediátricas
e as  suas  indicac¸ões  clínicas.
Fonte  de  dados:  revisão  na  base  de  dados  Pubmed,  compreendendo  os  termos  em  inglês  refer-
ente ao  tema  básico.
Síntese  dos  dados:  O  seu  espectro  de  ac¸ão  estende-se  desde  a  produc¸ão  de  mediadores  inﬂa-
matórios,  o  controle  da  hipersecrec¸ão  de  muco  e  modulac¸ão  de  mecanismos  de  defesa  do
hospedeiro.  O  potencial  benefício  dos  antibióticos  macrolídeos  foi  estudado  em  doenc¸as
pulmonares  como  a  ﬁbrose  cística,  as  bronquiectasias,  a  asma,  a  bronquiolite  aguda  e  as
bronquiectasias  não  ligadas  à  ﬁbrose  cística.  Diversos  estudos  avaliaram  os  benefícios  dos
macrolídeos  na  asma  resistente  a  terapia,  porém,  os  resultados  são  controversos  e  as  indicac¸ões
devem ser  limitadas  a  fenótipos  especíﬁcos.  Na  bronquiolite  viral  não  há  benefícios  consistentes
nos quadros  agudos,  embora  dados  recentes  mostrem  um  efeito  na  prevenc¸ão  de  sibilância
recorrente.  Em  pacientes  com  ﬁbrose  cística  os  resultados  também  são  contraditórios,  mas  o
consenso é  de  que  há  um  pequeno  benefício  clínico,  especialmente  para  os  pacientes  infecta-
dos por  P.  aeruginosa.  Também  não  foi  observada  ac¸ão  positiva  dos  macrolídeos  em  pacientes
com bronquiolite  obliterante  pós-infecciosa.  Crianc¸as  com  bronquiectasias  não  relacionadas
à ﬁbrose  cística  parecem  ter  claros  benefícios  em  relac¸ão  ao  uso  de  macrolídeos,  os  quais
mostraram vantagens  clínicas,  de  protec¸ão  ao  parênquima  e  na  func¸ão  pulmonar.
Conclusões:  O  uso  em  longo  prazo  de  macrolídeos  deve  ser  limitado  a  situac¸ões  altamente  sele-
cionadas,  especialmente  em  pacientes  com  bronquiectasias.  Avaliac¸ão  cuidadosa  dos  benefícios
e potenciais  danos  são  ferramentas  para  indicac¸ão  em  grupos  especíﬁcos.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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Macrolides  are  antibiotics  belonging  to  a  chemical  compound
family  characterized  by  the  presence  of  a  macrocyclic  lac-
tone  ring,  for  which  the  reference  drug  is  erythromycin.1
These  are  drugs  that  have  been  used  for  years  to  treat
respiratory  infections,  given  their  excellent  tissue  penetra-
tion  and  action  against  many  of  the  common  respiratory
pathogens,  including  Mycoplasma  species,  Chlamydia, and
Legionella.2,3 Macrolides  exert  their  antimicrobial  effect  by
binding  to  bacterial  ribosome,  speciﬁcally  the  50S  subunit,
promoting  protein  synthesis  inhibition.  The  effect  may  be
bacteriostatic  or  bactericidal,  depending  on  the  concentra-
4tion  and  susceptibility  of  microorganisms.
In  the  early  1980s,  positive  results  of  erythromycin
use  in  patients  with  a  disease  originally  described  in
Japan  and  known  as  acute  diffuse  panbronchiolitis  (DPB)
a
a
sroused  the  interest  of  physicians  and  researchers  on  the
mmunomodulatory  potential  of  macrolides.5 Acute  DPB
s  an  idiopathic  disease  characterized  by  distal  airway
bstruction,  mucoid  impaction,  and  dilation,  with  extensive
nﬂammatory  inﬁltration  of  neutrophils  and  CD8+  lympho-
ytes.  It  can  be  associated  with  infection  by  Pseudomonas
eruginosa  species  in  more  advanced  stages  and  develop
nto  extensive  bronchiectasis.6 The  use  of  erythromycin  is
ecommended  for  patients  with  this  disease,  representing
ne  of  the  main  therapeutic  resources;  it  is  believed  that
ts  action  mechanisms  include  anti-inﬂammatory  and  anti-
ucus  actions.6,7
In  an  extensive  review  of  action  mechanisms  of
acrolides  as  immunomodulators  in  lung  diseases,  Kanoh
nd  Rubin4 described  the  existing  evidence  regarding  the
ction  of  these  drugs  in  several  areas  of  pulmonary  and
ystemic  physiology,  including  modulation  of  inﬂammatory
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Table  1  Immunomodulatory  effects  of  macrolides.4
Target  Action
Effects  on  airway
secretion
Interference  with  ion  transport  in  epithelial  cells
Inhibition  of  mucus  hypersecretion
Interference  with  mucin  gene  expression
Anti-inﬂammatory
effects
Interference  with  cytokine  production  (IL-8,  TNF-alpha,  and  IL-6  reduction)
Reduction  in  adhesion  molecule  expression
Interference  with  chemotaxis  and  the  release  of  inﬂammatory  mediators  (including  reactive  oxygen
species) of  neutrophils  and  eosinophils,  interference  with  differentiation,  and  apoptosis  of  inﬂammatory
cells
Stabilization  of  respiratory  epithelium  through  tight-junction  modiﬁcation
Interference  with  the  proliferation  of  ﬁbroblasts  and  vascular  endothelial  cells  involved  in  angiogenesis
Effects on  cell
signaling
Interference  with  intracellular  calcium  signaling  pathway
Interference  in  the  mitogen-activated  protein  kinase  (MAPK)  system  via  action  on  the
extracellular-signal-regulated  kinases  (ERKs),  modulating  the  expression  of  transcription  factors
(especially  NF-kB)
Effects  on  bacteria  Interference  with  bacterial  adhesion
Inhibition  of  virulence  factors  (e.g.,  exotoxin  A,  elastase,  etc.)
Bioﬁlm  inhibition
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ytokine  synthesis,  adhesion  molecule  expression,  activity
nd  survival  of  inﬂammatory  and  respiratory  epithelial  cells,
n  addition  to  effects  on  airway  secretions  (Table  1).4
In  recent  years,  the  use  of  macrolides  in  a  number  of  res-
iratory  diseases  such  as  asthma,  acute  viral  bronchiolitis,
ystic  ﬁbrosis  (CF),  bronchiolitis  obliterans  (BO),  and  non-CF
ronchiectasis  has  increased  signiﬁcantly,  but  there  is  still
uch  controversy  about  the  unrestricted  use  of  macrolides
n  these  cases,4,5 either  due  to  concerns  about  the  emer-
ence  of  resistant  bacterial  strains,8,9 or  safety  concerns.10
he  purpose  of  this  review  article  was  to  evaluate  the  exist-
ng  data  in  the  literature  regarding  the  use  of  macrolides  in
linically  relevant  pediatric  respiratory  diseases.
ethods
 search  was  performed  in  the  PubMed  database,  compris-
ng  the  following  terms  in  English:  ‘‘macrolide  and  asthma’’;
‘macrolide  and  cystic  ﬁbrosis’’;  ‘‘macrolide  and  acute  viral
ronchiolitis’’;  ‘‘macrolide  and  bronchiolitis  obliterans’’;
nd  ‘‘macrolide  and  non-CF  bronchiectasis.’’
The  search  was  conducted  with  no  limitation  regarding
peciﬁc  periods,  seeking  to  include  the  most  relevant  publi-
ations  on  the  assessed  topics.  In  addition  to  the  descriptive
ext,  a  table  containing  the  summary  of  ﬁndings  with  rec-
mmendations  for  the  use  of  macrolides  in  the  assessed
onditions  was  included,  according  to  the  level  of  scientiﬁc
vidence  (Grading  of  Recommendations  Assessment,  Devel-
pment  and  Evaluation  --  GRADE  system).11
se of macrolides in pulmonary diseases
sthma  refractory  to  basic  treatmentsthma  is  an  airway  disease  characterized  by  chronic
nﬂammation,  bronchial  hyperresponsiveness,  and  airﬂow
imitation.  The  disease  manifests  clinically  with  recurrent
w
p
woughing,  wheezing,  and/or  dyspnea.  The  mechanisms
esponsible  for  the  maintenance  of  the  inﬂammatory
esponse,  which  is  characterized  by  the  increased  num-
er  of  activated  lymphocytes,  eosinophils,  neutrophils,  and
ast  cells  of  variable  shape,  are  only  partially  recognized,
ut  evidence  suggests  that  chronic  or  subacute  infections
ith  atypical  bacteria  such  as  Mycoplasma  pneumoniae
nd  Chlamidophila  pneumoniae  may  be  important  contrib-
tors  to  the  pathogenesis  and  severity  of  asthma  in  some
atients.3,12
In  addition  to  effective  antimicrobial  activity  for  the
bovementioned  agents,  macrolides  also  exhibit  anti-
eutrophil  immunomodulatory  activity,  which  makes  them
andidates  for  asthma  treatment.  Several  clinical  trials  have
een  performed  to  assess  the  effect  of  macrolides  on  dif-
erent  aspects  of  asthma  therapy,  such  as  acute  asthma,13
sthma  refractory  to  treatment,14 or  as  corticosteroid-
paring  agents.15
Most  of  these  studies  have  small  samples  and  are  sus-
eptible  to  random  biases  due  to  lack  of  power.  In  a
ystematic  review  published  in  2005,  Richeldi  et  al.16 ana-
yzed  seven  studies  (416  patients)  and  observed  some
ymptom  improvement,  but  no  impact  on  pulmonary  func-
ion  (forced  expiratory  volume  in  the  ﬁrst  second  [FEV1]),
hus  not  recommending  the  routine  use  of  this  therapy.  In
 more  recent  meta-analysis  that  included  a  total  of  12
andomized  controlled  trials,  no  signiﬁcant  improvement
n  FEV1  was  observed  after  macrolide  administration  for
hree  weeks  or  more.17 However,  the  joint  analysis  of  the
ata  showed  signiﬁcant  improvement  in  symptom  scores,
uality  of  life,  peak  expiratory  ﬂow,  and  bronchial  hyper-
eactivity  in  asthmatic  patients  treated  with  macrolides.  In
his  meta-analysis,  adverse  events  were  uncommon,  mostly
nimportant,  and  rarely  led  to  treatment  withdrawal.  There
ere  no  severe  cardiovascular  side  effects  reported  in  the
atients  treated  with  macrolides.17
Macrolides  appear  to  have  a  more  important  role  in  air-
ay  diseases  with  neutrophilic  inﬂammation,  such  as  CF  and
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Table  2  Summary  of  key  scientiﬁc  evidence  on  macrolide  use  in  lung  diseases,  with  recommendations  for  their  use  (based  on
the GRADE  system).11
Pathology  Study  types  and  key  ﬁndings  Recommendation
Asthma  refractory  to
treatment
Cochrane  systematic  review  (seven  studies,
416  patients)  --  no  effect  on  FEV1,  but  showing
symptom  and  peak  ﬂow  improvement.16
Meta-analysis  (12  studies,  831  patients)  --  no
effect  on  FEV1,  but  showing  symptom  and
quality  of  life  improvement.17
Their  systematic  use  is  not  recommended,
but  some  patient  subgroups  may  beneﬁt
(Grade  2B).
Acute viral
bronchiolitis
Cochrane  systematic  review  (two  studies,  281
patients)  --  no  differences  in  length  of  hospital
stay, duration  of  oxygen  therapy,  and
readmissions.26
Their  systematic  use  is  not  recommended
(Grade  1A).
Cystic Fibrosis  Meta-analysis  (eight  studies,  654  patients)  --
signiﬁcant  improvement  in  FEV1  and  FVC,
particularly  in  patients  chronically  infected
with  P.  aeruginosa.36
Cochrane  systematic  review  (ten  studies,  959
patients)  showing  signiﬁcant  lung  function
improvement,  reduction  of  acute  pulmonary
exacerbations,  and  weight  gain
improvement.37
Use  is  recommended  for  patients  with
chronic  infection  by  P.  aeruginosa  (Grade
1A).
Post-transplant
bronchiolitis
obliterans (PTBO)
Meta-analysis  (ten  studies,  140  patients)
showing  improvement  in  lung  function  (about
8% in  FEV1)  and  a  trend  to  reduction  in
mortality  from  PTBO.54
Use  is  recommended  in  PTBO  (Grade  1A).
Post-infectious
bronchiolitis
obliterans
Review of  42  cases  showing  unspeciﬁed  clinical
improvement  with  combination  of
corticosteroids  and  azithromycin.57
Insufﬁcient  evidence  to  recommend  their
use (Grade  2C).
Non-cystic  ﬁbrosis
bronchiectasis
Meta-analysis  of  ten  studies  (601  patients)  --
reduction  in  acute  exacerbations,  FEV1  fall
attenuation,  reduction  in  sputum  volume,  and
clinical  score  improvement,  but  increased  risk
of diarrhea  and  bacterial  resistance.64
Use  is  recommended  for  patients  with  at
least  three  pulmonary  exacerbations  or  two
admissions  in  the  last  12  months  (Grade
2A).
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Abronchiectasis.  The  inﬂammatory  proﬁle  in  the  patient’s  air-
way  has  been  recognized  as  one  of  the  main  determinants
of  response  to  treatment  with  macrolides.
However,  few  studies  have  speciﬁcally  assessed  their  efﬁ-
cacy  in  the  neutrophilic  asthma  phenotype.  Simpson  et  al.14
reported  a  signiﬁcant  decrease  in  Interleukin-8  (IL-8)  and
neutrophil  counts  in  the  sputum.  In  one  of  the  most  recent
controlled  trials,18 the  results  were  stratiﬁed  by  inﬂam-
matory  proﬁle,  identifying  a  signiﬁcant  reduction  in  the
number  of  exacerbations  in  patients  with  non-eosinophilic
phenotype.  In  this  case,  the  phenotype  was  deﬁned  by  the
absence  of  systemic  eosinophilia.18 It  is  important  to  recog-
nize  these  subtypes  associated  with  asthma  complexity,  as
asthma  therapy  is  advancing  toward  a  treatment  directed  to
different  phenotypes,  considering  the  great  variability  and
complexity  of  this  pathology.
In  addition  to  the  immunomodulating  effects,  the  ben-
eﬁcial  effects  of  azithromycin  in  severe  non-eosinophilic
asthma  could  also  be  due  to  its  antimicrobial  properties.
Chronic  respiratory  infection  with  atypical  bacteria  such
as  Mycoplasma  pneumoniae  and  Chlamydophila  pneumo-
niae  may  play  a  role  in  the  pathogenesis  of  uncontrolled
asthma.2
V
t
y
tIn  brief,  long-term  treatment  with  macrolides  in  asth-
atic  individuals  yields  controversial  results.  However,  a
ecent  meta-analysis  that  increased  the  statistical  power  of
he  analyses  showed  beneﬁts  in  several  asthma  outcomes,
ncluding  quality  of  life  and  symptoms,  although  there  was
o  improvement  in  FEV1.  Currently,  there  is  little  evidence
o  justify  the  routine  use  of  macrolides  in  asthma  treatment.
However,  in  some  subgroups  of  patients,  such  as
hildren  with  evidence  of  atypical  bacterial  infection,  non-
osinophilic  asthma  (or  neutrophilic)  may  beneﬁt  from
acrolide  effects.  Therefore,  there  are  no  recommenda-
ions  for  the  systematic  use  of  macrolides  in  patients  with
efractory  asthma,  but  they  can  be  indicated  as  adjunctive
herapy  in  the  treatment  of  speciﬁc  asthma  cases,  particu-
arly  in  some  speciﬁc  phenotypes  (Table  2).
cute  viral  bronchiolitis  and  recurrent  wheezingiral  bronchiolitis  is  an  acute,  potentially  severe  disease
hat  usually  affects  young  infants.  It  often  occurs  in  the  ﬁrst
ear  of  life  and  is  the  most  common  cause  of  hospitaliza-
ion  in  infants  in  the  1st  year  of  life.19 The  disease  responds
S da  Silva  Filho  LV  et  al.
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U56  
oorly  to  treatment,  including  antiviral  drugs.  Considering
hat  viruses  are  potent  inducers  of  production  and  release
f  cytokines  and  pro-inﬂammatory  chemokines,  the  poten-
ial  beneﬁt  of  immunomodulatory  and  anti-inﬂammatory
ctions  of  macrolides  has  also  been  assessed  in  respiratory
iral  infections,  although  in  small  studies  with  contradictory
esults.
In  a  double-blinded,  randomized,  placebo-controlled
rial,  Tahan  et  al.20 assessed  the  efﬁcacy  of  clarithromycin
dministered  daily  for  three  weeks  in  children  younger  than
 months  hospitalized  for  respiratory  syncytial  virus  (RSV)
ronchiolitis.  Nine  subjects  were  excluded  from  analysis  due
o  corticosteroid  use,  which  left  12  individuals  in  the  group
hat  received  clarithromycin  and  nine  in  the  placebo  group.
he  use  of  clarithromycin  was  associated  with  a  statisti-
ally  signiﬁcant  reduction  in  hospital  length  of  stay,  oxygen
se  time,  need  for  2-agonists,  and  hospital  readmission
ithin  six  months.20 This  study  received  harsh  criticism  in
etters  sent  to  the  journal  due  to  errors  in  the  statistical
nalysis,  questionable  methodology,  and  small  number  of
atients.21,22
However,  the  doubts  regarding  the  effect  of  macrolides
n  acute  viral  bronchiolitis  were  even  more  pronounced,
uggesting  the  need  for  further  research  in  the  area.  Three
ubsequent  randomized  and  placebo-controlled  trials  with
arger  samples  (n  =  71/184/97)  were  published,  carried  out
n  infants  aged  <24  months,  hospitalized  for  clinical  picture
f  viral  bronchiolitis.  The  macrolide  assessed  in  these  stud-
es  was  azithromycin,  and  its  use  was  not  superior  to  placebo
egarding  the  length  of  hospital  stay  (primary  endpoint),
ays  of  symptoms,  or  need  for  supplemental  oxygen.23--25
herefore,  the  use  of  macrolides  is  not  recommended  for
he  treatment  of  infants  with  acute  viral  bronchiolitis26
Table  2).
Recently,  a  pilot  study  in  hospitalized  children  with
ronchiolitis  due  to  RSV  showed  that  treatment  with
zithromycin  for  two  weeks,  when  added  to  the  routine
are  of  bronchiolitis,  resulted  in  a  reduction  of  an  airway
nﬂammation  marker  (neutrophilic  inﬂammation)  and  IL-8  in
asal  lavage  samples.  Additionally,  the  participants  treated
ith  azithromycin  took  longer  to  develop  recurrent  wheez-
ng  (third  episode  of  wheezing  after  acute  bronchiolitis)  and
ad  signiﬁcantly  fewer  days  with  respiratory  symptoms  dur-
ng  the  following  year.27
IL-8  has  a  potent  neutrophil  chemotactic  effect  and
ctivates  immune  system  cells  in  response  to  infection  by
SV.  An  increase  in  IL-8  in  the  upper  airways  has  been
eported  as  a  marker  of  acute  bronchiolitis  severity.  The
ubsequent  neutrophil  degranulation  may  result  in  epithe-
ial  cell  damage.  Therefore,  an  intervention  to  reduce
L-8  levels  in  the  airways  could  attenuate  the  damage
ue  to  the  effect  on  neutrophils  and,  subsequently,  pre-
ent  respiratory  sequelae  of  recurrent  wheezing  caused  by
SV.28
Nonetheless,  the  relatively  small  sample  size  studied  to
ate  is  an  important  limitation  to  make  a  deﬁnitive  assess-
ent  of  the  usefulness  of  this  intervention  for  recurrent
heezing  prevention.  Therefore,  although  the  general  trend
oward  better  clinical  outcomes  is  encouraging,  it  cannot
e  concluded  that  treatment  with  azithromycin  for  acute
ronchiolitis  reduces  the  occurrence  of  recurrent  wheez-
ng.  These  potential  beneﬁcial  effects  must  be  evaluated
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pigure  1  Computed  tomography  images  of  an  adolescent  cys-
ic ﬁbrosis  patient’s  chest,  showing  mucoid  impaction  (black
rrows)  and  bronchiectasis  (white  arrows).
n  larger  and  more  deﬁnitive  clinical  trials  with  a  longer
ollow-up  duration.
ystic  ﬁbrosis
F  is  a  genetic  disease  that  leads  to  chronic  bronchitis,
ucoid  impaction,  and  bronchiectasis29 (Fig.  1),  showing
imilar  characteristics  to  those  of  acute  diffuse  panbron-
hiolitis.  Many  CF  patients  develop  chronic  P.  aeruginosa
nfections,  with  worsening  of  the  inﬂammatory  process
nd  progressive  decline  in  pulmonary  function.30 Possible
ction  mechanisms  of  macrolides  in  CF  include  P.  aerug-
nosa  virulence  reduction,  decreased  bacterial  adherence
o  the  respiratory  epithelium,  reduced  bacterial  motility,
nd  interference  with  bioﬁlm  production.31,32 Among  the
mmunomodulatory  actions  of  macrolides  in  the  host  with
F,  factors  include  the  interference  with  elastase  produc-
ion  by  neutrophils  (main  effectors  of  the  inﬂammatory
esponse  in  CF),  inhibition  of  inﬂammatory  cytokine  pro-
uction  by  alveolar  macrophages,  and  decrease  in  mucus
ypersecretion.31,32
The  macrolide  most  often  used  in  CF  patients  has  been
zithromycin,  and  the  ﬁrst  encouraging  clinical  trial  was
ublished  in  2002,  evaluating  41  patients  with  CF  in  a  cross-
ver,  double-blind,  randomized,  placebo-controlled  trial  for
5  months.33 The  primary  endpoint  was  the  change  in
EV1,  and  the  drug  dose  was  administered  at  two  weight
anges  (250  mg/day,  if  weight  ≤40  kg  or  500  mg/day,  if
eight  >40  kg).  The  authors  observed  signiﬁcant  pulmonary
unction  improvement  (5.4%,  95%  CI  =  0.8--10.5%)  in  the
roup  receiving  azithromycin  when  compared  to  the  placebo
roup,  and  no  signiﬁcant  difference  was  observed  regarding
acteria  concentration  in  sputum,  exercise  tolerance,  and
uality  of  life.  The  treatment  was  also  well  tolerated,  with
o  signiﬁcant  adverse  events.33
Subsequently,  a  new  multicenter,  double-blind,  ran-
omized,  placebo-controlled  trial  was  conducted  in  the
nited  States  with  a sample  of  185  patients  chronically
nfected  with  P.  aeruginosa  and  older  than  6  years.34 The
zithromycin  dose  was  equal  to  that  of  the  abovementioned
tudy,  but  use  was  limited  to  three  times  per  week.  The
rimary  endpoint  was  also  FEV1,  and  the  authors  showed  a
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signiﬁcant  difference  between  the  treatment  and  placebo
groups  (6.2%,  95%  CI  =  2.6--9.8%).  Other  encouraging  results
were  a  35%  reduction  in  the  risk  of  acute  pulmonary  exacer-
bation  and  signiﬁcant  weight  gain  in  patients  that  received
azithromycin.34
This  same  group  evaluated  the  effect  of  azithromycin  in
CF  patients  not  infected  with  P.  aeruginosa35;  this  time,  the
use  of  azithromycin  for  24  weeks  did  not  result  in  signiﬁcant
FEV1  improvement  when  compared  with  the  placebo  group,
but  there  was  a  signiﬁcant  reduction  in  the  occurrence  of
acute  pulmonary  exacerbations  in  the  group  treated  with
azithromycin.35
A  recent  meta-analysis  assessing  the  use  of  macrolides  in
CF  patients  included  six  randomized  placebo-controlled  tri-
als  (654  patients).36 Treatment  with  azithromycin  resulted
in  signiﬁcant  FEV1  and  FVC  improvement,  particularly
in  patients  chronically  infected  with  P.  aeruginosa. The
incidence  of  side  effects  was  not  signiﬁcantly  different
between  the  placebo  group  and  the  group  treated  with
azithromycin.36
In  a  systematic  review  of  macrolide  use  in  CF,  a  total
of  10  studies  were  included  (959  patients).37 Four  clinical
trials  (549  patients)  showed  signiﬁcant  improvement  in  pul-
monary  function  when  comparing  azithromycin  with  placebo
(mean  difference  in  a  six-month  period  was  3.97%,  95%
CI  =  1.74--6.19%).
Patients  on  azithromycin  showed  a  decrease  in  the  occur-
rence  of  acute  pulmonary  exacerbations,  required  oral
antibiotics  less  frequently,  and  had  higher  weight  gain
and  lower  rate  of  identiﬁcation  of  S.  aureus  in  respi-
ratory  secretion  cultures.  Adverse  effects  were  unusual,
although  an  increase  in  macrolide  resistance  was  observed.
The  authors  concluded  that  azithromycin  has  a  small  ben-
eﬁcial  effect  in  the  treatment  of  CF  patients,  with  a
dose  administration  schedule  of  three  times  per  week,
for  six-month  periods;  therefore,  its  use  is  recommended
for  patients  with  chronic  infection  by  P.  aeruginosa
(Table  2).
However,  considering  the  scarce  long-term  data  and  the
concern  about  the  development  of  bacterial  resistance  to
macrolides,  the  current  evidence  is  not  strong  enough  to
indicate  azithromycin  for  all  CF  patients.37
Other  macrolides  were  assessed  on  a  less  systematic  basis
in  CF  patients  (studies  with  small  samples,  published  as
congress  abstracts),  or  showed  to  be  ineffective  in  this  group
of  patients.  Clarithromycin  was  assessed  in  a  double-blind
crossover  study  in  63  CF  patients  for  12  months,  and  no  ben-
eﬁcial  effect  was  observed  on  pulmonary  function  (primary
endpoint),  or  the  frequency  of  acute  pulmonary  exacerba-
tions,  quality  of  life,  and  inﬂammatory  cytokine  proﬁle  in
sputum.38
Bronchiolitis  obliterans
BO  is  a  rare  disease  that  manifests  as  a  chronic  obstruc-
tive  pulmonary  disease,  and  can  affect  healthy  individuals
or  patients  submitted  to  bone  marrow  (BMT)  or  solid  organ
transplantation.39 In  case  of  patients  that  underwent  lung
transplantation,  the  likelihood  of  developing  bronchiolitis
obliterans  over  time  is  so  high  that  it  affects  70%  of  survivors
ten  years  after  the  transplantation.40
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The  process  involves  the  obstruction  of  small  airways,
nd  two  types  of  histopathological  patterns  were  origi-
ally  described:  a  pattern  of  lymphoid  tissue  proliferation,
onstituting  intraluminal  polyps  (initially  known  as  bron-
hiolitis  obliterans  organizing  pneumonia  [BOOP])  and  a
attern  of  concentric  airway  ﬁbrosis,  known  as  constric-
ive  bronchiolitis.41 This  constrictive  pattern  was  the  one
ost  often  found  in  biopsies  of  children  with  post-infectious
ronchiolitis  obliterans  in  the  state  of  São  Paulo,  Brazil.42
The  physiopathological  mechanism  of  BO  is  not  fully
nown,  but  there  is  evidence  that  severe  epithelial  injury
f  the  distal  airways  triggers  an  intense  process  of  uncon-
rolled  ﬁbroproliferation.39 Among  the  triggering  insults
f  bronchiolitis  obliterans  are  the  following:  toxic  gas
nhalation,43 severe  viral  respiratory  infections,  especially
y  adenovirus,44 autoimmune  diseases,45 and  graft  vs.  host
eactions.46
Clinically,  patients  with  BO  exhibit  progressive  respira-
ory  difﬁculty,  initially  dry  cough  (which  may  progress  to
uppurative),  and  obstructive  patterns  of  varying  degrees
t  the  spirometry,  usually  with  signiﬁcant  air  trapping  and
ack  of  response  to  bronchodilator  therapy.39
Radiologically,  a  pattern  of  regional  hyperinﬂation  inter-
persed  with  normal  areas  can  be  observed,  characterizing
 mosaic  pattern  on  computed  tomography  of  the  chest.
his  pattern  is  frequently  seen  in  many  obstructive  diseases
nd  is  not  speciﬁc  for  bronchiolitis  obliterans,  particularly  in
nfants.  In  post-infectious  BO,  the  tomographic  ﬁnding  with
he  highest  diagnostic  sensitivity  is  bronchiectasis.47
The  treatment  of  BO  in  patients  undergoing  transplan-
ation  (BMT  or  lung)  usually  involves  immunosuppressive
rug  adjustments,  including  steroids,  cyclosporine,  and  cal-
ineurin  inhibitors,39 but  there  is  evidence  that  azithromycin
an  beneﬁt  many  patients,  probably  due  to  its  effect  on
eutrophilic  airway  inﬂammation  and  IL-8.48
Initial  studies  in  patients  with  bronchiolitis  obliterans
ost-BMT  were  encouraging,  showing  improvement  in  lung
unction  and  disease  stabilization,49 but  in  a  more  recent
andomized,  double-blind  trial,  Lam  et  al.50 did  not  identify
ny  effect  in  patients  with  post-BMT  bronchiolitis  obliterans,
ven  though  they  were  relatively  advanced  disease  cases.50
However,  experience  in  patients  submitted  to  lung  trans-
lantation  has  been  more  encouraging,  and  some  studies
ave  shown  improvement  in  lung  function  and  inﬂamma-
ory  parameters  in  bronchoalveolar  lavage,51,52 also  with
n  impact  on  these  patients’  survival.53 In  a recent  meta-
nalysis,  comprising  data  from  ten  studies  and  140  patients,
ingah  et  al.54 reported  positive  effects  on  lung  function
about  8%  in  FEV1)  after  macrolide  use  in  patients  with  post-
ransplant  bronchiolitis  obliterans,  in  addition  to  a  trend  in
educed  mortality  from  BO.54 Thus,  macrolide  use  is  rec-
mmended  for  patients  undergoing  bone  marrow  or  solid
rgan  transplantation  who  manifest  symptoms  or  functional
bnormalities  suggestive  of  BO  (Table  2).
In  cases  of  post-infectious  BO,  the  approach  includes  the
se  of  systemic  and  inhaled  corticosteroids,  usually  associ-
ted  with  the  use  of  bronchodilators  or  anticholinergics.55,56
t  is  noteworthy  that  there  have  been  no  controlled  inter-
ention  studies  with  these  drugs  or  even  with  azithromycin,
ut  in  a recent  review  study  of  42  cases  in  China,  Li
t  al.57 reported  successful  treatment  in  84%  of  cases
sing  a  combination  of  corticosteroids  and  azithromycin.
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158  
here  is  no  evidence  to  recommend  the  systematic  use
f  macrolides  in  patients  with  post-infectious  bronchiolitis
bliterans  (Table  2).
on-CF  bronchiectasis
ronchiectasis  is  the  pathological  bronchial  dilatation,
sually  associated  with  mucosal  thickening  and  impaired
ecretion  clearance,  resulting  in  accumulation  of  secretion,
hronic  suppurative  cough,  and  pulmonary  function  loss.58
onsidered  a  nearly  universal  phenomenon  in  patients  with
F,  it  can  also  be  observed  in  several  other  clinical  situa-
ions,  such  as  immunodeﬁciencies,  ciliary  dyskinesia,  and  as
 sequela  to  severe  pulmonary  infections.58 They  are  usually
ssociated  with  a  chronic  process  of  infection  and  predom-
nantly  neutrophilic  inﬂammation  and,  in  this  context,  the
se  of  macrolides  could  be  indicated  to  alleviate  symptoms,
educe  the  frequency  of  exacerbations,  and  provide  some
unctional  improvement  over  time.59
Although  the  causes  can  be  multiple  and  the  prevalence
aries  signiﬁcantly  in  different  populations,  there  is  evi-
ence  that  speciﬁc  groups,  such  as  indigenous  populations  in
eveloped  countries  and  children  from  low-income  families,
re  more  susceptible  to  develop  non-CF  bronchiectasis.9,60,61
There  are  some  recent  randomized  studies  on  the  use
f  macrolides  in  adult  patients  with  non-CF  bronchiecta-
is  using  azithromycin  and  erythromycin,  all  demonstrating
 reduction  in  exacerbation  frequency,  with  no  impact  on
atients’  lung  function.62 Only  one  randomized  study  eval-
ating  the  use  of  macrolides  in  children  or  adolescents  with
on-CF  bronchiectasis  was  published  in  a  speciﬁc  population
f  aboriginal  origin  in  New  Zealand  and  Australia.9 A  total
f  44  children  were  assessed  in  the  placebo  group  and  45  in
he  study  group,  which  received  azithromycin  30  mg/kg  in  a
eekly  administration.  A  signiﬁcant  reduction  in  frequency
f  acute  exacerbations  was  observed  in  the  group  receiving
he  drug,  but  there  was  a  signiﬁcant  increase  in  the  isolation
f  bacterial  strains  resistant  to  azithromycin  in  nasal  swab
amples  from  the  study  group  at  the  end  of  the  study.9
In  a  recent  meta-analysis,  the  compilation  of  data
rom  ten  studies  (601  patients)  showed  that  macrolide  use
esulted  in  a  reduction  in  acute  exacerbations,  FEV1  fall
ttenuation,  reduction  in  sputum  volume,  and  clinical  score
mprovement,  but  also  in  an  increased  risk  of  diarrhea  and
acterial  resistance.63,64 Although  most  of  the  evidence  of
his  therapeutic  approach  comes  from  studies  carried  out
n  adult  patients,  the  effects  in  children  and  adolescents
ppear  to  be  similar63,64 (Table  2).  The  criteria  for  this  ther-
peutic  indication,  however,  must  include  lack  of  clinical
ontrol  with  the  usual  treatment,  such  as  at  least  three
cute  pulmonary  exacerbations  or  two  hospitalizations  in
he  last  12  months.65 Additionally,  the  treatment  period
ust  be  limited  (12--24  months)  to  assess  whether  there  is
eﬁnitely  a  response.65
onclusionslthough  the  in  vitro  effect  and  studies  in  speciﬁc  popu-
ations  have  demonstrated  the  anti-inﬂammatory  action  of
acrolides  in  pediatric  respiratory  diseases,  the  magnitude
f  the  impact  on  clinical  responses  is  still  debatable.  Further
1da  Silva  Filho  LV  et  al.
tudies  are  necessary  to  deﬁne  populations  with  clear  ben-
ﬁts.  Perhaps  the  greatest  appeal  for  the  use  of  macrolides
t  is  the  lack  of  new  and  affordable  options  for  high-impact
iseases  such  as  asthma,  viral  bronchiolitis,  and  CF.
A  major  concern  regarding  the  overuse  of  macrolides,
n  general,  is  bacterial  resistance  induction.  A  number  of
tudies  have  demonstrated  their  overuse  induces  resistance,
specially  in  pneumococcal  strains.66,67 Therefore,  further
tudies  to  determine  their  actual  importance  in  the  treat-
ent  of  diseases  mentioned  in  this  review,  as  well  as  dose
nd  frequency-of-use  assessments,  are  extremely  important
o  that  medical  practice  does  not  lead  to  more  problems
han  beneﬁts  for  the  population.
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